Cargando…

Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020

This cross-sectional study uses data from the US Food and Drug Administration (FDA) to review the postmarketing requirements and commitments attached to new vaccines approved for use in the past 15 years in the United States.

Detalles Bibliográficos
Autores principales:	Moneer, Osman, Lee, ChangWon C., Avorn, Jerry, Kesselheim, Aaron S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087952/ https://www.ncbi.nlm.nih.gov/pubmed/33929526 http://dx.doi.org/10.1001/jamanetworkopen.2021.8530

Ejemplares similares

Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
por: Feldman, Daniel, et al.
Publicado: (2022)

Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration
por: Jiao, Kuo, et al.
Publicado: (2019)

Characteristics of US Patients and Prescribers Using Hydroxychloroquine During the COVID-19 Pandemic
por: Rome, Benjamin N., et al.
Publicado: (2021)

Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
por: Wallach, Joshua D., et al.
Publicado: (2019)

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
por: Cherla, Avi, et al.
Publicado: (2021)

Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments
por: Skydel, Joshua J., et al.
Publicado: (2019)

Variation in Use of Lung Cancer Targeted Therapies Across State Medicaid Programs, 2020-2021
por: Roberts, Thomas J., et al.
Publicado: (2023)

Demographic Characteristics of Participants in Trials Essential to US Food and Drug Administration Vaccine Approvals, 2010–2020
por: Zhang, Audrey D., et al.
Publicado: (2021)

Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis
Publicado: (2018)

Association of expedited review programmes with postmarketing safety events of new drugs approved by the US food and drug administration between 2007 and 2017
por: Zhu, Xingyue, et al.
Publicado: (2022)

Postmarket Surveillance of Medical Devices: A Comparison of Strategies in the US, EU, Japan, and China
por: Kramer, Daniel B., et al.
Publicado: (2013)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2021)

Clinicians’ Contributions to the Development of Coronary Artery Stents: A Qualitative Study of Transformative Device Innovation
por: Kesselheim, Aaron S., et al.
Publicado: (2014)

US public investment in development of mRNA covid-19 vaccines: retrospective cohort study
por: Lalani, Hussain S, et al.
Publicado: (2023)

Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration
por: Egilman, Alexander, et al.
Publicado: (2021)

Postmarket Clinical Evidence for High-Risk Therapeutic Medical Devices Receiving Food and Drug Administration Premarket Approval in 2010 and 2011
por: Rathi, Vinay K., et al.
Publicado: (2020)

Physicians’ Trust in the FDA’s Use of Product-Specific Pathways for Generic Drug Approval
por: Kesselheim, Aaron S., et al.
Publicado: (2016)

Medical Students' Exposure to and Attitudes about the Pharmaceutical Industry: A Systematic Review
por: Austad, Kirsten E., et al.
Publicado: (2011)

Public sector financial support for late stage discovery of new drugs in the United States: cohort study
por: Nayak, Rahul K, et al.
Publicado: (2019)

Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action
por: Olivier, Timothée, et al.
Publicado: (2021)

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia
por: Hwang, Thomas J., et al.
Publicado: (2022)

Conflict of Interest Reporting by Authors Involved in Promotion of Off-Label Drug Use: An Analysis of Journal Disclosures
por: Kesselheim, Aaron S., et al.
Publicado: (2012)

Paying Physicians to Prescribe Generic Drugs and Follow-On Biologics in the United States
por: Sarpatwari, Ameet, et al.
Publicado: (2015)

Variations in Use of Diabetes Drugs With Cardiovascular Benefits Among Medicaid Patients
por: Zhai, Mike Z., et al.
Publicado: (2022)

Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020
por: Miljković, Miloš D., et al.
Publicado: (2022)

Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006–2020
por: Lythgoe, M. P., et al.
Publicado: (2021)

Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018
por: Fan, Min, et al.
Publicado: (2022)

Risk for Postmarket Black Box Warnings in FDA-Approved Monoclonal Antibodies
por: Hagan, John B., et al.
Publicado: (2021)

Projected spending for brand-name drugs in English primary care given US prices: a cross-sectional study
por: Liu, Michael, et al.
Publicado: (2020)

Time for the US food and drug administration approval of condoms for anal intercourse
por: Nguyen, Brian T., et al.
Publicado: (2019)

Participation of Black US Residents in Clinical Trials of 24 Cardiovascular Drugs Granted FDA Approval, 2006-2020
por: Chen, Siliang, et al.
Publicado: (2021)

Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov
por: Bothwell, Laura E, et al.
Publicado: (2018)

Public funding for transformative drugs: the case of sofosbuvir
por: Barenie, Rachel E., et al.
Publicado: (2021)

Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
por: Parikh, Ravi B., et al.
Publicado: (2023)

Overview of the Premarketing and Postmarketing Requirements for Drugs Granted Japanese Conditional Marketing Approval
por: Matsushita, Shunsuke, et al.
Publicado: (2021)

U.S. Food and Drug Administration: Review for the Emergency Physician of Approval Process and Limitations
por: Zuabi, Nadia, et al.
Publicado: (2016)

Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
por: Liang, Fei, et al.
Publicado: (2020)

Review of Evidence Supporting 2022 US Food and Drug Administration Drug Approvals
por: Kaplan, Robert M., et al.
Publicado: (2023)

Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review
por: Wang, Bo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6lb04s81v467a1auos90lh576l